Skip to main content

What is Braftovi used to treat?

Medically reviewed by Judith Stewart, BPharm. Last updated on Dec 30, 2024.

Official Answer by Drugs.com

Braftovi is used in combination with other drugs to treat patients with advanced melanoma, advanced non-small cell lung cancer and advanced colorectal cancer with BRAF gene mutations.

Braftovi is an oral small molecule BRAF kinase inhibitor.

Melanoma

Braftovi (encorafenib) is used in combination with Mektovi (binimetinib) for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.

Roughly 50% of patients diagnosed with metastatic melanoma test positive for the BRAF mutation, and it is the most common genetic mutation in metastatic melanoma.

Braftovi is not indicated for the treatment of patients with wild-type BRAF melanoma.

Colorectal Cancer

Braftovi is used in combination with Erbitux (cetuximab) for the treatment of adult patients with
metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy.

Braftovi is also used in combination with Erbitux (cetuximab) and mFOLFOX6 (fluorouracil, leucovorin and oxaliplatin) for the first-line treatment of patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test.
- This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

BRAF mutations are estimated to occur in up to 15% of people with metastatic colorectal cancer.

Braftovi is not indicated for treatment of patients with wild-type BRAF CRC.

Non-Small Cell Lung Cancer

Braftovi is used in combination with Mektovi (binimetinib) for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test.

BRAF mutations are estimated to occur in 2% to 5% of people with metastatic non-small cell lung cancer.

Braftovi is not indicated for the treatment of patients with wild-type BRAF NSCLC.

Related questions

References
  • Braftovi (encorafenib) prescribing information. Revised 12/2024. Pfizer Inc. New York, NY. Accessed Dec 29, 2024 at https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210496s017lbl.pdf

Read next

What is the success rate of Keytruda?

In general, PD-1 immune checkpoint inhibitors like Keytruda have been shown to significantly prolong overall survival (OS) in some patients with various cancer types, but Keytruda does not always work for everyone. Continue reading

What is the CAPOX (XELOX) chemotherapy regimen?

The CAPOX chemotherapy regimen includes capecitabine and oxaliplatin. It is a widely used and effective chemotherapy protocol for advanced colorectal and other gastrointestinal cancers. It combines oral capecitabine and intravenous oxaliplatin, administered in 3-week cycles.

Continue reading

How long does it take for Keytruda to work?

The time it takes for Keytruda to work can vary based on the type and stage of cancer. Typically, a response to treatment becomes apparent within 2-4 months of starting Keytruda. This timeframe is referred to as "time to response," which measures when a patient's cancer begins to show signs of responding to the treatment. You can find the specific "time to response" data from clinical trials in the table below. Continue reading

See also:

Related medical questions

Drug information

Related support groups